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Nanoceria (cerium oxide nanoparticles) toxicity is currently
a concern because of its use in motor vehicles in order to
reduce carbon monoxide (CO), nitrogen oxides (NOx), and
hydrocarbons in exhaust gases. In addition, many questions
arise with respect to its biomedical applications exploiting
its potential to protect cells against irradiation and oxidative
stress. Indeed, toxicology studies on nanoceria report results
that seem contradictory, demonstrating toxic effects in some
1. Introduction
The increased use of nanoparticles (NPs) and nanoparti-
cle-based materials raises many concerns about their impact
on health. Some reviews[1–3] have commented this issue for
various such materials, demonstrating the importance of
the research on biosafety. However, as noted in most of
these reviews, toxicity tests are often hardly reproducible
among different research groups. For example, the size of
NPs,[4] their surface properties,[5] the type of cells,[4] and the
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studies, protective effects in others, and sometimes little or
no effect at all. The variability in the experimental setups
and particle characterization makes these studies difficult to
compare and the toxicity of newly developed nanoceria ma-
terials challenging to predict. This microreview aims to com-
pare the toxicity of nanoceria in terms of preparation method,
particle size, concentration, host organism, and exposure
method.
exposure method[6] all influence the outcome of studies on
their toxicity in such a way that it may lead to different
results. On the other hand, the increased use of NPs and
nanoparticulate materials as well as their potential in vari-
ous applications render the study of their toxicity highly
essential.
Nanoparticulate materials based on ceria (cerium oxide,
CeO2) have many applications in diverse fields, including
petroleum refining, polishing agents, and coatings.[7] Nano-
ceria is a promising material for energy-related applications
such as in fuel cells, hydrogen production and purification,
and water splitting.[8] Its use in three-way catalysts, espe-
cially as the mixed oxide, CeO2–ZrO2, in motor vehicles,
has proven very valuable for environmental issues, as it re-
duces the emission of polluting gases by controlling the air-
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to-fuel ratio thanks to its oxygen-storage capacity. It thus
enables the simultaneous oxidation of CO and hydro-
carbons and the reduction of NO.[8,9] Ceria nanoparticles
were demonstrated to have no significant adverse effects on
the cytotoxicity in a 3D in vitro co-culture model of the
epithelial airway barrier for diesel exhaust exposure in such
a way that their use as a fuel-borne catalyst can be advan-
tageous, though its long-term effects still remain to be eluci-
dated.[10] They have also been proposed for biomedical ap-
plications, for example in sun creams[11] and more recently
in the form of nanocontainers as drug carriers for the pre-
vention of, for example, implant infections.[12] Furthermore,
it was demonstrated that ceria NPs can protect cells against
irradiation and oxidative stress;[13,14] hence their biological
activity and toxicity are of great interest. The present review
therefore focuses on the protective and toxic effects of
nanoceria and aims to compare some of the variables that
can influence the protection or toxicity as reported by vari-
ous research groups. Yokel et al.[13] compared the biological
effects depending on nanoceria size, host subject, and expo-
sure method, whereas Karakoti et al.[14] focused on the ef-
fects according to nanoceria preparation methods. We
hereby present a more extensive comparison and discussion
on both the preparation methods and the experimental
setup. We focus on the preparation methods in combination
with particle size and concentration, host organism, and ex-
posure method, in order to observe the effects that the par-
ticle preparation has on the protective and toxic effects of
nanoceria. This extensive and visual comparison, also pre-
sented in form of a table, can provide a good starting point
for the design of nanoceria materials with more predictable
toxicity.
2. Protective Effects of Ceria Materials
The key property that makes ceria such an interesting
material for biomedical applications is its oxygen-storage
capacity.[15,16] In fact, ceria normally contains many defects,
that is, oxygen vacancies, which enable it to rapidly give up
or take up oxygen atoms in a reversible manner. When an
oxygen atom is released according to Equation (1), two of
the four neighboring Ce4+ atoms get reduced to their +3
oxidation state in order to equilibrate the charge, as de-
picted in Figure 1.[16,17]
CeO2 h CeO2–x + 1/2 x O2 (g) where 0  x  0.5 (1)
Figure 1. Simplified schematic representation of the charge redistri-
bution in CeO2 upon the occurrence of an oxygen vacancy.
Adapted with permission from ref.[16]
The remarkable oxygen-storage capacity and antioxidat-
ive property of ceria have also been attributed to its radical
scavenging,[18] protection against irradiation,[19] and UV-fil-
tering properties.[20] This leads to the protection of eukary-
otic cells against oxidative stress, as it was previously re-
ported in many studies.[21,22] Niu et al.[23] and Korsvik et
al.[24] have proposed a mechanism, shown in Equations (2)
and (3), by which ceria can scavenge radicals thanks to its
redox potential.
O2·– + Ce4+  O2 + Ce3+ (2)
O2·– + Ce3+ + 2H+  H2O2 + Ce4+ (3)
However, the redox potential of ceria might also lead to
toxic pro-oxidative effects,[25,26] (see Table 1) and it was re-
cently demonstrated that the radioprotection efficacy of
nanoceria through free-radical scavenging is also dependent
on the X-ray radiation spectra.[27] It was furthermore
shown that the smaller the size of the nanoceria particles,
the higher the amount of Ce3+ and hence that of oxygen
defects in the structure and on the surface of the particles.[7]
3. Toxicity of Nanoceria
It is generally assumed that toxicity increases as the NP
size gets smaller.[28] This can be explained by the fact that
cellular uptake is facilitated for smaller NPs and they are
therefore more likely to be distributed in the blood stream
or even in the central nervous system. In addition, smaller
particles have a larger surface area per mass unit in such a
way that they are potentially more active.[28,29] In the case
of nanoceria, a larger ratio of surface area to volume leads
to a larger surface Ce3+/Ce4+ ratio, which could be related
to a higher toxicity for smaller ceria NPs.[6] However, this
is not always applicable for all ceria materials. In fact, a
study demonstrated that larger ceria particles can have a
higher toxicity towards eukaryotic cells.[30] Another in vivo
study demonstrated that inhaled ceria nanomaterials are
more toxic than ceria micromaterials in terms of mass con-
centration, but less toxic in terms of surface area concentra-
tion. When the authors expressed their results in terms of
particle number, then both materials had a similar toxic-
ity.[31] The lower toxicity with smaller ceria particle size can
also be explained by the higher tendency of smaller NPs to
form agglomerates.[32] It is also well known that the surface
properties, such as the zeta potential, of NPs play a key role
in their biocompatibility.[33] The zeta potential of particles
can be modified by changing, for example, the pH of the
solution[34] or by using a coating.[35] Kumar et al.[32] have
reviewed the way physicochemical properties of the tested
nanoceria can influence the results of the cytotoxic studies.
In short, they noted that a minor modification in the syn-
thesis route may have a major impact on the biological ac-
tivity and toxicity of ceria and pointed out that reproducib-
ility in nanomaterials synthesis often constitutes a chal-
lenge. Kumar et al.[32] also discussed many gaps that need
to be filled with regard to nanoceria toxicity. For example,
a better understanding of the influence of the precursor’s
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purity, nanoceria morphology, binding sites, and long-term
biotransformation in vivo is still strongly needed.
Some other studies[13,36,37] also reported a low toxicity of
ceria towards eukaryotic cells, even though no protection
effect was observed. For example, Gaiser et al.[36] demon-
strated that, even though they adhered to the cell mem-
brane and entered the cells, ceria NPs that were smaller
than 25 nm or had a size between 1 and 5 μm did not show
any significant cytotoxicity. A study by Yokel et al.,[38] who
injected 30 nm nanoceria intravenously into the blood of
rats, demonstrated that this material did not cross the
blood–brain barrier (BBB). They also observed that nano-
ceria remained in the body, especially in the spleen, liver,
and bone marrow, for long time periods of up to 90 days
and that the bigger-sized nanoceria (55 nm) tended to ag-
gregate at the site of injection rather than being distributed
in the body.[13,38] Their observations are in accordance with
results reported by other research groups.[25] Nanoceria has
also been reported to have a low acute toxicity towards
Calu-3 lung epithelial cells and Raw264.7 macrophages and
to have no effect on transepithelial electrical resistance in
such a way that nanoceria did not damage the epithelial
barrier.[37]
Some publications reported a time- and dose-dependent
toxicity of ceria nanomaterials.[38–40] De Marzi et al.,[22]
who studied the one-day and ten-day effects of ceria expo-
sure on different cell lines, found that the toxicity assays are
greatly dependent on the systems being studied. In fact,
they observed that ceria had different effects according to
the cell line of interest, the human adenocarcinomic alveo-
lar basal epithelial A549 cell line being the most sensitive to
the presence of ceria at low concentrations. Three different
studies on nanoceria toxicity against A549 cells (Table 1) all
demonstrated adverse effects[12,41,42] and are thus in accord-
ance with the observations of De Marzi et al.,[22] who did
not observe any toxic effect of ceria after 24 hours of expo-
sure but reported a genotoxic effect for all cell lines after
10 days.
The synthesis protocol, which dictates, for example, the
particle size, structure, and surface properties of ceria, also
contributes to their effect on biological systems. Karakoti
et al.[14] have reviewed the effect of the preparation method
on ceria toxicity and have indicated that a synthesis at low
temperature often leads to less toxic and even more antioxi-
dative ceria particles. This observation was partly explained
by the fact that the chemicals used in the synthesis of the
ceria nanomaterials influence the zeta potential,[34] which
in turn influences their aggregation behavior, protein ad-
sorption, and cytotoxicity.[34,43] They also found that the
effects of chemicals can be altered by high temperatures.
This was also observed by Peng et al.,[44] who compared the
cytotoxicity of nanoceria prepared by either precipitation
or hydrothermal methods. Nanoceria prepared by precipi-
tation formed smaller aggregates in such a way that their
acute inflammatory effect was higher and their deposition
in the lungs was faster. On the other hand, the hydrother-
mally prepared nanoceria produced more reactive oxygen
species (ROS), causing inflammation and cytotoxicity. This
seems to be in contrast with the fact that nanoceria particles
prepared at high temperatures tend to be bigger, more
dense, and to have fewer oxygen vacancies and defects.[14]
A shape effect was reported by Ji et al.,[45] whereby long
ceria nanorods (greater than or equal to 200 nm) induced
inflammatory responses while short ceria nanorods were
nontoxic.
Hussain et al.[46] suggested many possible toxic effects of
ceria on human peripheral blood monocytes. In their ex
vivo study, they first observed an up-regulation in auto-
phagy caused by an inhibition of p53 proteins, which are
the proteins that regulate the cell cycle and prevent cancer
formation, leading to cell death. In addition to that, they
observed the swelling and elongation of mitochondria fol-
lowing exposure to nanoceria, which further leads to
apoptosis. Induced apoptosis due to nanoceria exposure
was also observed by other research groups.[12,47] This effect
is attributed to an overproduction of ROS and a diminution
of the antioxidant species glutathione (GSH).[47]
The uptake kinetics plays a key role in interpreting the
toxicity of materials. Some cells can rapidly internalize ceria
nanoparticles. For example, 24 hours after exposure to
aerosolized ceria nanoparticles, 80% of the nanoparticles
were detected intracellularly in A549 lung cells, and the rate
of nanoceria internalization is limited by the particle mass
transport.[48] Within cells, ceria nanoparticles tend to ag-
glomerate.[48,49] Cytotoxic effects of nanoceria can be
greatly reduced by preventing the internalization of the NPs
into cells, for example by encapsulating them into a hydro-
gel. Weaver and Stabler[50] demonstrated that their alginate
hydrogel prevented the phagocytosis of dextran-coated
nanoceria and thus reduced their cytotoxicity, while pre-
serving the antioxidative and protective properties of these
particles. On the other hand, it was observed that when no
cytotoxicity is observed, the cellular uptake can even en-
hance the protection against ROS, and thus reduce
apoptosis.[50]
These different reports demonstrated various protective
as well as toxic effects for nanoceria, as already pointed out
in other reviews on other nanomaterials as well.[6,28,32,51]
Furthermore, the combination of materials, for example the
use of nanoceria with other particles such as those in diesel
exhaust, may increase their toxicity[52] and render the bios-
afety of nanoceria more challenging to determine.
4. Comparison and Discussion
Table 1 lists representative examples of all reported ef-
fects of nanoceria materials according to their preparation
method, size, and the tested organism. When available, the
effective concentration EC20, that is, the concentration at
which the nanoceria material induced a 20% decrease in
cell viability, was provided. This table was partly inspired
by the reviews of Yokel et al.[13] and Karakoti et al.[14] The
publications in which the method of fabrication and the
particle sizes were not specified, in which the nanoceria was
purchased from suppliers, or in which the nanoceria is em-
bedded into a matrix were omitted.
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The first observation that can be made by looking at
Table 1 is that studies demonstrating protective effects or
no adverse effects of ceria are more numerous than those
demonstrating negative adverse effects. Among the 44 mate-
rials reported in Table 1, 16 (36%) demonstrated adverse
effects, 12 (27%) demonstrated little or no adverse effects
and 17 (39%) demonstrated protective effects. Schubert et
al.[30] have shown that ceria materials that have a cytotoxic
effect on nerve cells can nonetheless be beneficial and pro-
tect these cells against harmful irradiation.
Another observation from Table 1 is that, in contrast
with the suggestion of Karakoti et al.,[14] the method and
Table 1. Effects of ceria on eukaryotic cells depending on the preparation method, particle size, cell type, and test type.
temperature of preparation are far from being enough to
predict the toxicity of ceria nanomaterials, even though
these factors contribute to the biological effects of nano-
ceria. In fact, we do observe a slight relation between the
temperature and the biological activity. Among the 17 ma-
terials synthesized at high temperatures (above 100 °C), 9
(53%) had adverse effects, 4 (23.5%) had little effect, and 4
(23.5%) had protective effects, whereas among the 27 mate-
rials prepared at low temperatures (less than or equal to
100 °C), 7 (26%) had adverse effects, 8 (30%) had little ef-
fect, and 13 (48%) had protective effects. One nanoceria
material was considered twice because it had protective ef-
4
ht
tp
://
do
c.
re
ro
.c
h
Table 1. (Continued).
[a] r.t.: room temperature. [b] SRB: sulforhodamine B.[74] [c] LDH: lactate dehydrogenase.[75] [d] MTT assay: 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (or tetrazolium salt) assay.[76] [e] DMEM: Dulbecco’s modified Eagle’s medium. [f] WST-1: water soluble
tetrazolium salts [or 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, also called cell proliferation reagent].[77] [g]
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.[78]
fects in spite of its cytotoxic behavior. On the other hand,
we observed that protective effects are more commonly, but
not always, found for small NPs (smaller than 20 nm),
whereas no size dependence is observed for the adverse ef-
fects. In fact, among the 31 nanoceria with diameters
smaller than 20 nm, 7 (22%) had adverse effects, 8 (26%)
had little effect, and 16 (52%) had protective effects. For the
13 nanoceria materials with diameters larger than 20 nm,
including the material found to have both adverse and pro-
tective effects, 9 (69%) had adverse effects, 4 (31%) had
little effect, and 1 (8%) had protective effects. Finally, can-
cer-derived cells tend to be more sensitive to the presence
of nanoceria. When a cancerous cell line was used (10 tests),
5 (50%) tests resulted in adverse effects, 1 (10%) in little
effect, and 4 (40%) in protective effects. When a normal cell
line was used (35 tests), 11 (31%) resulted in adverse effects,
9 (26%) in little effect, and 15 (43%) in protective effects.
As already demonstrated by Perez et al.,[41] nanoceria tend
to offer less antioxidative protection to cancerous cells than
to normal cells, hence there seems to be a potential for the
application of nanoceria in cancer therapy.
Interpreting and comparing toxicity results often repre-
sents a challenge. Results can easily be misinterpreted. As
an example, we have recently presented results on ceria
nanocontainers with and without silver content.[12] We ob-
served that, while using the lactate dehydrogenase (LDH)
assay, the ceria nanocontainers did not show any cytotoxi-
city effect. On the other hand, when we observed A549 cells
with a confocal laser scanning microscope, we saw the
shrinkage of cell sizes and membranes, which are typical
signs of apoptosis. It is therefore important to use more
than one technique to determine whether a material really
has a toxic effect. In addition, in our experimental setup,
we allowed cells to grow directly on ceria nanocontainers,
which provides a very rough surface for cells and probably
increases apoptosis. Since in the final application, these ce-
ria nanocontainers are to be embedded in a biomaterial
coating, the exposure method is not fully representative of
this application. Comparing the cytotoxicity results for free
nanoceria with those for nanoceria embedded in a biocom-
patible matrix could enable a better evaluation of the bio-
safety of this material.[12]
In order to fully assess the toxicology and biological ac-
tivity of ceria materials, a complete characterization of the
material, that is its NP size, agglomerate size, zeta potential,
surface properties and porosity, should be included in the
5
ht
tp
://
do
c.
re
ro
.c
h
toxicity study. It is also very likely that the oxygen vacancies
play an important role as they confer redox-properties upon
nanomaterials. However, to determine these vacancies,
physical analytical tools need to be used, which are often
less available in the bio-oriented laboratories. In addition, a
full characterization of the test conditions (pH of culture
medium, pH variation, salt concentration, etc.) would also
be essential for in vitro tests, as these properties can affect
the surface properties and stability of materials.[32,34] When
possible, a characterization of the nanoceria recovered after
in vitro or in vivo experiments could be valuable in order
to understand the effects of nanoceria on biological systems
and the variations in toxicity and biological activities.
Finally, as it has already been pointed out by Kumar
et al.,[32] a better collaboration between research groups of
different fields could be very beneficial in building a de-
tailed database on ceria toxicity. This would be especially
useful when two groups observed different effects for sim-
ilar nanoceria materials in order to determine the cause(s)
of these differences.
5. Conclusions
Toxicity results for ceria often seem contradictory, and a
unique reliable toxicity assessment for ceria is still miss-
ing.[1,11] In addition, as mentioned above, ceria toxicity tests
are greatly dependent on synthesis conditions, physical and
chemical properties, surface properties, cell type, exposition
method, and various other characteristics. The use of a
coating has also a considerable impact on nanoceria toxic-
ity in such a way that its toxicity can be reduced by using
a coating that prevents aggregation and precipitation.[79] All
these variables make the comparability between the dif-
ferent ceria materials very difficult to achieve and thus ceria
toxicity difficult to assess.[3] For this reason, it is a good
idea to perform toxicity tests for the newly developed mate-
rials under conditions that mimic the most likely potential
organism exposure. As long as a detailed database for ceria-
based materials is not developed, it is essential to test all
newly developed ceria materials designated for biomedical
applications in vitro and in vivo by using an experimental
setup as representative of the final application as possible.
We hope that this review will help other researchers to de-
sign their experimental setups and to make the right choice
of nanoceria materials for the desired functions. Despite all
the conflicting evidence on ceria toxicity, this material has
very promising applications in areas such as drug delivery
systems,[12] neurodegenerative disease therapy,[80] medical
imaging,[81] and cancer treatment.[1,82]
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